Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04460547
Recruitment Status : Not yet recruiting
First Posted : July 7, 2020
Last Update Posted : July 7, 2020
Sponsor:
Information provided by (Responsible Party):
Dr Shiva Shankar Bugude, Qassim University

Brief Summary:
On 11th of March 2020, WHO characterized COVID-19 infection as a Pandemic. After the COVID-19 infection is declared as a Pandemic there was an outburst regarding COVID-19 Research. The Research interest led to registration of Interventional and Observational studies world wide. There are constant efforts by Health care workers to seek information regarding the Interventional and Observational studies which can help in decision making regarding effective handling of COVID-19 infected patients. It is also important to track on the happenings in various frontiers of COVID-19 Research in view of historical interest and clinical relevance. This Observational Cross sectional study aims to explore the completed Researches in WHO-compliant registries to understand the trends of COVID-19 Research. This study aims to get a birds eye view of ongoing COVID-19 Research scenario worldwide. This study results can directly benefit the worldwide Academicians and Health Care Professionals to understand the ongoing COVID-19 Research trends.

Condition or disease Intervention/treatment
COVID-19 Drug: Convalescent Plasma Transfusion Drug: Hydroxychloroquine Drug: DAS181 Drug: Ivermectin Drug: Interferon Beta-1A

Show Show detailed description

Layout table for study information
Study Type : Observational
Estimated Enrollment : 200 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic: An Observational Study
Estimated Study Start Date : July 25, 2020
Estimated Primary Completion Date : August 15, 2020
Estimated Study Completion Date : September 20, 2020

Group/Cohort Intervention/treatment
Completed Interventional studies
Interventional studies in the WHO-compliant registries database which are registered and completed before 11th March 2020.
Drug: Convalescent Plasma Transfusion
Convalescent Plasma Transfusion to COVID-19 infected patients.

Drug: Hydroxychloroquine
Hydroxychloroquine administration to COVID-19 infected patients.

Drug: DAS181
DAS181 administration to COVID-19 infected patients.

Drug: Ivermectin
Ivermectin administration to COVID-19 infected patients.

Drug: Interferon Beta-1A
Interferon Beta-1A administration to COVID-19 infected patients.

Completed Observational studies
Observational studies in the WHO-compliant registries database which are registered and completed before 11th March 2020.
Drug: Convalescent Plasma Transfusion
Convalescent Plasma Transfusion to COVID-19 infected patients.

Drug: Hydroxychloroquine
Hydroxychloroquine administration to COVID-19 infected patients.

Drug: DAS181
DAS181 administration to COVID-19 infected patients.

Drug: Ivermectin
Ivermectin administration to COVID-19 infected patients.

Drug: Interferon Beta-1A
Interferon Beta-1A administration to COVID-19 infected patients.




Primary Outcome Measures :
  1. Geographical distribution of the interventional studies after 11th of March 2020. [ Time Frame: 15th of August 2020 ]
    To understand the geographical distribution of the interventional studies after 11th of March 2020.

  2. Geographical distribution of the Observational studies after 11th of March 2020. [ Time Frame: 15th of August 2020 ]
    To understand the geographical distribution of the Observational studies after 11th of March 2020.

  3. Monthly Research study completion rate as per geographic distribution of the Research. [ Time Frame: 15th of August 2020 ]
    To understand the monthly Research study completion rate as per geographic distribution of the Research.


Secondary Outcome Measures :
  1. Statistical correlation of the interventional studies Research with developed, developing and under developed countries. [ Time Frame: 15th of August 2020 ]
    To understand the statistical correlation of the interventional studies Research with developed, developing and under developed countries.

  2. Statistical correlation of the observational studies Research with developed, developing and under developed countries. [ Time Frame: 15th of August 2020 ]
    To understand the statistical correlation of the observational studies Research with developed, developing and under developed countries.

  3. Statistical correlation of the Drug based interventional studies Research with developed, developing and under developed countries. [ Time Frame: 15th of August 2020 ]
    To understand the statistical correlation of the Drug based interventional studies Research with developed, developing and under developed countries.

  4. Statistical correlation of the Diagnostic test based interventional studies Research with developed, developing and under developed countries. [ Time Frame: 15th of August 2020 ]
    To understand the statistical correlation of the Diagnostic test based interventional studies Research with developed, developing and under developed countries.

  5. Statistical correlation of the Device based interventional studies Research with developed, developing and under developed countries. [ Time Frame: 15th of August 2020 ]
    To understand the statistical correlation of the Device based interventional studies Research with developed, developing and under developed countries.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Probability Sample
Study Population
Subjects who are infected with COVID-19. Healthy Volunteers who respond to survey. Subjects who have recently recovered from COVID-19 infection.
Criteria

Inclusion Criteria:

Interventional studies in the WHO-compliant registries database which are registered and completed after 11th of March 2020 until 15th of August 2020.

Observational studies in the WHO-compliant registries database which are registered and completed after 11th of March 2020 until 15th of August 2020.

Exclusion Criteria:

Interventional studies in the WHO-compliant registries database which are registered and completed before 11th March 2020.

Observational studies in the WHO-compliant registries database which are registered and completed before 11th March 2020.

Layout table for additonal information
Responsible Party: Dr Shiva Shankar Bugude, Assistant Professor, Qassim University
ClinicalTrials.gov Identifier: NCT04460547    
Other Study ID Numbers: COAHS
First Posted: July 7, 2020    Key Record Dates
Last Update Posted: July 7, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: The Research data will be extracted from the WHO-compliant registry databases.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Dr Shiva Shankar Bugude, Qassim University:
Research trends, COVID-19, Pandemic, Interventional studies, Observational studies
Additional relevant MeSH terms:
Layout table for MeSH terms
Interferons
Interferon-beta
Interferon beta-1a
Hydroxychloroquine
Ivermectin
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antirheumatic Agents
Immunologic Factors
Physiological Effects of Drugs
Adjuvants, Immunologic